BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 16770087)

  • 1. Sensitivity analysis of cost factors for various therapy options in the treatment of follicular lymphoma.
    Schmitz S; Aly F; Steinmetz T; Diehl V; Rehwald U
    Onkologie; 2006 Jun; 29(6):258-64. PubMed ID: 16770087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges.
    Lokich JJ; Moore CL; Anderson NR
    Cancer; 1996 Jul; 78(2):294-9. PubMed ID: 8674006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs of drug delivery for CHOP, COP/CVP, and fludarabine: an international assessment.
    Herold M; Hieke K
    Value Health; 2003; 6(2):167-74. PubMed ID: 12641867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of malignant non-Hodgkin's lymphoma. Economic impact of rituximab (Mabthera) versus conventional chemotherapy].
    Malliti M; Junot H; Fievet MH; Gabarre J; Taright N; Vernant JP; Thuillier A
    Ann Med Interne (Paris); 2003 May; 154(3):139-47. PubMed ID: 12910040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma.
    Dundar Y; Bagust A; Hounsome J; McLeod C; Boland A; Davis H; Walley T; Dickson R
    Health Technol Assess; 2009 Jun; 13 Suppl 1():23-8. PubMed ID: 19567210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Economic analysis of rituximab in combination with cyclophosphamide, vincristine and prednisolone in the treatment of patients with advanced follicular lymphoma in Portugal].
    Braga P; Carvalho S; Gomes M; Guerra L; Lúcio P; Marques H; Negreiro F; Pereira C; Silva C; Teixeira A
    Acta Med Port; 2010; 23(6):1025-34. PubMed ID: 21627880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.
    Sabater E; López-Guillermo A; Rueda A; Salar A; Oyagüez I; Collar JM
    Appl Health Econ Health Policy; 2016 Aug; 14(4):465-477. PubMed ID: 27090915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costs of chemotherapy for indolent follicular non-Hodgkin's lymphoma in the UK: an observational study.
    Hutchinson J; Lloyd A; Gray A; Gale R; Hancock B
    Acta Haematol; 2006; 115(1-2):28-34. PubMed ID: 16424646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of extended adjuvant rituximab for US patients aged 65-70 years with follicular lymphoma in second remission.
    Hayslip JW; Simpson KN
    Clin Lymphoma Myeloma; 2008 Jun; 8(3):166-70. PubMed ID: 18650180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden.
    Kasteng F; Erlanson M; Hagberg H; Kimby E; Relander T; Lundkvist J
    Acta Oncol; 2008; 47(6):1029-36. PubMed ID: 18607857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of costs for infusion versus bolus chemotherapy administration--Part two. Use of charges versus reimbursement for cost basis.
    Lokich JJ; Moore CL; Anderson NR
    Cancer; 1996 Jul; 78(2):300-3. PubMed ID: 8674007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.
    Hornberger JC; Best JH
    Cancer; 2005 Apr; 103(8):1644-51. PubMed ID: 15756658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma.
    van Agthoven M; Kramer MH; Sonneveld P; van der Hem KG; Huijgens PC; Wijermans PW; Kluin-Nelemans HC; Schaafsma MR; Biesma DH; Mattijssen V; Uyl-de Groot CA; Hagenbeek A
    Haematologica; 2005 Oct; 90(10):1422-32. PubMed ID: 16219580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective analysis of first-line treatment for follicular lymphoma based on outcomes and medical economics.
    Muneishi M; Nakamura A; Tachibana K; Suemitsu J; Hasebe S; Takeuchi K; Yakushijin Y
    Int J Clin Oncol; 2018 Apr; 23(2):375-381. PubMed ID: 29063983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic burden of follicular non-Hodgkin's lymphoma.
    Foster T; Miller JD; Boye ME; Russell MW
    Pharmacoeconomics; 2009; 27(8):657-79. PubMed ID: 19712009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world costing analysis for diffuse large B-cell lymphoma in British Columbia.
    Costa S; Scott DW; Steidl C; Peacock SJ; Regier DA
    Curr Oncol; 2019 Apr; 26(2):108-113. PubMed ID: 31043812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of rituximab in follicular lymphoma.
    Johnston KM; Bolbocean C; Connors J; Peacock S
    Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):569-77. PubMed ID: 23140274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New treatment options have changed the survival of patients with follicular lymphoma.
    Fisher RI; LeBlanc M; Press OW; Maloney DG; Unger JM; Miller TP
    J Clin Oncol; 2005 Nov; 23(33):8447-52. PubMed ID: 16230674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.